| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Compass Therapeutics Inc. | CTX-009 (DLL4 X VEGF-A bispecific) - (COMPANION-002) | Biliary tract cancer (BTC) | Phase 2/3 | Data Released | Intravenous | Oncology |
| Compass Therapeutics Inc. | CTX-471 with tovecimig (CTX-009) | Solid tumors | Phase 2 | Trial Planned | Intravenous | Oncology |
| Compugen Ltd. | Rilvegostomig - (ARTEMIDE-Bil01) | Biliary Tract Cancer | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Connect Biopharma Holdings Limited | CBP-201 | Chronic rhinosinusitis with nasal polyps (CRSwNP) | Phase 2 | Subcutaneous | Respiratory | |
| Connect Biopharma Holdings Limited | Rademikibart - (Seabreeze STAT Asthma) | Asthma | Phase 2 | Data Released | Inhalation | Respiratory |
| Connect Biopharma Holdings Limited | Rademikibart | Atopic dermatitis (AD) | NDA Filing | Ongoing | Oral | Immunology |
| Connect Biopharma Holdings Limited | Icanbelimod (CBP-307) | Ulcerative Colitis (UC) | Phase 2b | Data Released | Oral | Gastroenterology |
| Connect Biopharma Holdings Limited | CBP-201 | Atopic dermatitis | Phase 2b | Trial Discontinued | Subcutaneous | Immunology |